The second-generation dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus exhibits a favorable safety profile.

In the COMPONENT trial for rheumatoid arthritis (RA), vidofludimus did not exhibit higher rates of many of the adverse effects known to occur with the US FDA-approved DHODH inhibitors leflunomide and teriflunomide.

The high selectivity for DHODH and lack of off-target effects of vidofludimus positions it as a promising selective immunomodulatory agent for use in a number of different immune-related diseases.